Eagle Pharmaceuticals Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 21c, Revenues Miss
May 10, 2021 6:55 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $0.86, $0.21 better than the analyst estimate of $0.65. Revenue for the quarter came in at $41.2 million versus the consensus estimate of $45.41 million.
First Quarter 2021
Total revenue for Q1 2021 was $41.2 million, compared to $46.0 million in Q1 2020, primarily reflecting decreased product sales of RYANODEX® and royalty revenue of BENDEKA®.
Q1 2021 net loss was $0.4 million, or $0.03 per basic and... More